(Total Views: 691)
Posted On: 07/28/2020 12:50:25 AM
Post# of 153903
Re: MD VIROLOGIST #45313
MDV,
I agree with all that you have posted, with the exception that I believe a hostile takeover or LBO would be difficult with the attention Leronlimab will very shortly receive. This will likely produce quite the scramble among multiple suitors to have the hand of Cytodyn at the dance. Of course, like the science of Leronlimab, finance at this level is well beyond my experience.
Even as a small time investor, it appears that there is substantial room for improvement in communication and strategic planning. It feels as though the recognition of multiple indications for Leronlimab has been overwhelming, causing forward progress on any indication to slow.
I hope that, in addition to new advisors addressing clinical exploration and development, executives with big pharm experience are brought on board to assist with more business development.
I agree with all that you have posted, with the exception that I believe a hostile takeover or LBO would be difficult with the attention Leronlimab will very shortly receive. This will likely produce quite the scramble among multiple suitors to have the hand of Cytodyn at the dance. Of course, like the science of Leronlimab, finance at this level is well beyond my experience.
Even as a small time investor, it appears that there is substantial room for improvement in communication and strategic planning. It feels as though the recognition of multiple indications for Leronlimab has been overwhelming, causing forward progress on any indication to slow.
I hope that, in addition to new advisors addressing clinical exploration and development, executives with big pharm experience are brought on board to assist with more business development.
(1)
(0)
